[go: up one dir, main page]

WO2015113102A1 - Structures à base de carbone auto-assemblées et procédés associés - Google Patents

Structures à base de carbone auto-assemblées et procédés associés Download PDF

Info

Publication number
WO2015113102A1
WO2015113102A1 PCT/AU2015/000034 AU2015000034W WO2015113102A1 WO 2015113102 A1 WO2015113102 A1 WO 2015113102A1 AU 2015000034 W AU2015000034 W AU 2015000034W WO 2015113102 A1 WO2015113102 A1 WO 2015113102A1
Authority
WO
WIPO (PCT)
Prior art keywords
xaa
spacer
graphene
layered
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2015/000034
Other languages
English (en)
Inventor
Mark BIGGS
Matthew PENNA
Meisam Valizadeh KIAMAHALLEH
Milan MIJAJLOVIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovation and Commercial Partners Pty Ltd
Loughborough University
Original Assignee
Adelaide Research and Innovation Pty Ltd
Loughborough University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900273A external-priority patent/AU2014900273A0/en
Application filed by Adelaide Research and Innovation Pty Ltd, Loughborough University filed Critical Adelaide Research and Innovation Pty Ltd
Publication of WO2015113102A1 publication Critical patent/WO2015113102A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/15—Nano-sized carbon materials
    • C01B32/182—Graphene
    • C01B32/184—Preparation
    • C01B32/19—Preparation by exfoliation
    • C01B32/192—Preparation by exfoliation starting from graphitic oxides
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/15—Nano-sized carbon materials
    • C01B32/182—Graphene
    • C01B32/194—After-treatment

Definitions

  • the present invention relates generally to novel layered graphene and related structures and materials; methods for producing, through self-assembly, novel layered graphene and related structures or materials of controlled pore size.
  • graphene and related materials such as, for example, graphene oxide (GO), reduced graphene oxide (rGO) and chemically-doped graphene have attracted considerable attention due to their exceptional inherent properties that result from, amongst other things, their two dimensional character.
  • GO graphene oxide
  • rGO reduced graphene oxide
  • chemically-doped graphene have attracted considerable attention due to their exceptional inherent properties that result from, amongst other things, their two dimensional character. 1
  • the exceptional electrical properties of graphene 1 has made it a target of interest in the development of various electrical components such as batteries and sensors.
  • considerable research has also been directed towards use of graphene in composite materials.
  • graphene and related materials have been a target of interest in the biomedical field with suggestions that they may prove useful in the field of drug delivery and biosensors.
  • the first main approach for producing such materials is through insertion of inorganic spacing elements such as carbon black, 3 randomly 4"10 and vertically aligned 11 ,12 carbon nanotubes, mesoporous carbon nanoparticles, 14 iron oxide nanorods, 15 ruthenium dioxide nanoparticles, 16 gold nanoparticles 17"21 or tin oxide nanoparticles 22 or nanorods, 23 either in the solution or vapour phase.
  • inorganic spacing elements such as carbon black, 3 randomly 4"10 and vertically aligned 11 ,12 carbon nanotubes, mesoporous carbon nanoparticles, 14 iron oxide nanorods, 15 ruthenium dioxide nanoparticles, 16 gold nanoparticles 17"21 or tin oxide nanoparticles 22 or nanorods, 23 either in the solution or vapour phase.
  • a second approach is through insertion of polymers between the sheets, including those that react with the graphene-based material such as polyaniline, 24 polyallylamine, 25 and regenerated cellulose 26 and those that are polymerized between the sheets such as polypyrrole. 27 None of these approaches provide a high degree of control over the inter-layer spacing or its uniformity due to the challenges in precisely controlling the size of the spacing units.
  • a third approach is use of metal ions that not only push apart the individual graphene or graphene-related sheets, but also cross-link them laterally. 28 Whilst use of ions gives tighter control over the pore size, the range of pore sizes is very limited indeed and still of the order of 1 nm. The intercalated ions are also easily removed depending on the solution conditions.
  • a fourth approach is the insertion of molecular linkers between sheets of graphene- related materials via chemical reaction between the linker molecules and some of the oxygen and other functionalities on the graphene-related sheets.
  • This has been realized in a number of ways including p-phenylenediamine (PPD), 29 Ni(ll) aza-macrocyclic complexes, 30 benzenediboronic acid, 31 and 3,3'-diaminobenzidine and related compounds.
  • PPD p-phenylenediamine
  • 29 Ni(ll) aza-macrocyclic complexes 29 Ni(ll) aza-macrocyclic complexes
  • 30 benzenediboronic acid 31 and 3,3'-diaminobenzidine and related compounds.
  • 32 The pore sizes accessible here are small, however, due to the constraint on the size of the molecules involved. Where pores sizes much larger than the molecule are claimed, as in the case of PPD, 29 this reflects an unpredictable process over which one would anticipate major issues with control
  • a fifth approach is through use of a monolayer of aryl azobenzene linkers with one end of the linker chemical bound to a graphene sheet and the other physically adsorbed to the adjacent graphene sheet. 33 Although this approach gives finer control over the distance between two successive graphene sheets in this example, the size range is severely limited by the lack of rigidity in the molecules beyond the short scale.
  • the above review demonstrates that there are two major issues with the state of the art to date in the field. The first is the inability to control to a high degree the spacing between the individual layers of graphene or graphene-related material (i.e. pore size) for anything other than the smallest spacing where use of metal ions facilitate finer control, albeit only under certain controlled conditions.
  • Xu et a/. 34 used DNA to yield a three dimensional GO-based material. There is, however, no claim that the DNA act to separate the GO layers, and this is unlikely to be the case given the claimed material formation mechanism.
  • Others 35 have used amino acids to achieve some form of spacing, but this was felt to be via electrostatic repulsion/attraction between the charged amino acids akin to the mechanism associated with metal ions.
  • Wu et a/. 36 have proposed the use of a peptide to self-assemble a GO hydrogel for drug delivery applications. Once again, however, there is no claim that the peptides create pores of a given size by sitting between the individual GO layers, with the peptide design being such as to induce the random assembly of the GO.
  • a spacer molecule comprising: at least first and second binding parts adapted to non-covalently bond at least a first graphene sheet to a second graphene sheet, said spacer comprising at least 9 amino acid residues and wherein when in a solution comprising two or more graphene sheets said spacer molecule contacts first and second graphene sheets to provide a layered structure and a predetermined space between at least the first graphene sheet and the at least second graphene sheet to provide a porous layered graphene structure.
  • graphene includes graphene oxide, reduced graphene, doped graphene and related carbon based materials.
  • a spacer middle portion separating first and second end groups comprising at least 9 amino acid residues wherein when in a solution comprising two or more graphene sheets said spacer molecule contacts first and second graphene sheets to provide a layered structure and a predetermined space between at least the first graphene sheet and the at least second graphene sheet to provide a porous layered graphene structure.
  • said first end group comprises one or more amino acids or modified amino acids.
  • said second end group comprises one or more amino acids or modified amino acids.
  • said first and/or said second end group comprises one or more aromatic amino acids or modified amino acids.
  • said aromatic amino acid is selected from the group consisting of: histidine, phenylalanine, tryptophan, or tyrosine.
  • said spacer middle portion comprises 9 to at least 50 amino acids or modified amino acids.
  • the spacer molecule can include one or more natural or modified amino acids. Modified amino acids can be naturally or non-naturally occurring.
  • the spacer molecule can be polar or non-polar and can include polar or non-polar amino acids or modified amino acids to alter the hydrophobicity or lipophilicity of the porous layered graphene structure. Examples of naturally occurring polar amino acids include glutamine, asparagine, histidine, serine, threonine, tyrosine, cysteine, methionine and tryptophan and modified amino acid variants thereof.
  • non-polar, or hydrophobic amino acids examples include alanine, isoleucine, leucine, phenylalanine, valine, proline and glycine and including modified amino acid variants thereof.
  • the combinations of polar and non-polar amino acids can be used to alter the hydrophobicity or lipophilicity of the porous layered graphene structure.
  • said spacer middle portion comprises one or more polar amino acids.
  • said spacer middle portion comprises one or more non-polar amino acids.
  • said spacer middle portion comprises at least 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 or at least 44 amino acids. In a preferred embodiment of the invention said spacer middle portion comprises over at least part of its length an alpha helix.
  • said spacer middle portion comprises over at least part of its length a beta sheet.
  • said alpha helix comprises the same amino acid residues, for example amino acids selected from the group consisting of: methionine, alanine, leucine, glutamine, lysine or arginine. It will be apparent this embodiment comprises an alpha helix comprising essentially of, for example poly-arginine or poly-lysine. In an alternative preferred embodiment of the invention said alpha helix comprises alternating, different amino acids selected from the group consisting of: methionine, alanine, leucine, glutamine, lysine or arginine. It will be apparent this embodiment comprises an alpha helix with, for example, alternating arginine and lysine amino acids.
  • Xaa- ⁇ and/or Xaa 2 is an aromatic amino acid
  • Xaa 3 and/or Xaa 4 is glycine
  • Xaa 5 to Xaa 10 comprise at least 5 amino acids selected from the group: methionine, alanine, leucine, glutamine, lysine or arginine;
  • Xaan and/or Xaa 12 is glycine
  • Xaa 13 and/or Xaa 14 is an aromatic amino acid.
  • said spacer molecule comprises amino acids selected from the amino acid sequence: Xaai Xaa 2 Xaa 3 Xaa 4 Xaa 5 Xaa 6 Xaa 7 Xaa 8 Xaa 9 Xaa 10 Xaan Xaa 12 Xaa 13 Xaa 14 [SEQ ID NO: 1 ]
  • Xaa ! and/or Xaa 2 is an aromatic amino acid
  • Xaa 3 and/or Xaa 4 is glycine
  • Xaa 5 to Xaa 10 comprise at least 5 amino acids selected from the group: tyrosine, phenylalanine, tryptophan, threonine, valine or isoleucine, optionally Xaa 5 to Xaa 10 can include one or more aromatic amino acid residue
  • 2 is glycine
  • Xaa 13 and/or Xaa 14 is an aromatic amino acid.
  • said spacer comprises the amino acid sequence:
  • Xaa 5 to Xaa 10 comprises the same amino acid residues wherein said amino acid residues are selected from the group consisting of: methionine, alanine, leucine, glutamine, lysine or arginine.
  • said spacer comprises the amino acid sequence:
  • Xaa2 Xaas Xaa 4 Xaas Xaag Xaa 7 Xaa8 Xaag Xaa-io Xaan Xaa-12 Xaa-i3 Xaa-
  • Xaa 5 to Xaa 10 comprises alternating amino acid residues wherein said amino acid residues are selected from the group consisting of: methionine, alanine, leucine, glutamine, lysine or arginine.
  • said spacer comprises the amino acid sequence: FFGGEEEEEEGGFF [SEQ ID NO: 3], or a modified amino acid sequence wherein said modified amino acid sequence is at least 75% identical to the amino acid sequence FFGGEEEEEEGGFF [SEQ ID NO: 3] and that retains or has enhanced graphene binding.
  • the invention features peptide sequences having at least 80% identity with FFGGEEEEEEGGFF [SEQ ID NO: 3], or fragments and functionally equivalent peptides thereof.
  • the peptides have at least 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, still more preferably at least 97% or 98% identity, and most preferably at least 99% identity with the amino acid sequence set for as FFGGEEEEEEGGFF [SEQ ID NO: 3].
  • a spacer comprising FFGGEEEEEEGGFF [SEQ ID NO: 3] can be modified by one or more substitutions, additions, deletions, truncations which may be present in any combination. Among preferred modifications are those that vary by conservative amino acid substitutions. Such substitutions are those that substitute a given amino acid by another amino acid of like characters. Most highly preferred are modified peptides which retain the same function and activity as the reference peptide from which it varies. In a preferred embodiment of the invention said peptide comprising or consisting of an amino acid sequence selected from the group consisting of:
  • a layered graphene structure comprising one or more spacers according to the invention.
  • said layered graphene structure includes: at least a first graphene layer and at least a second graphene layer, at least one spacer layer, wherein said at least one spacer layer includes at least one spacer unit, the spacer unit including a middle portion and an upper end and a lower end, so as to provide a desired predetermined space between the at least first graphene layer and the at least second graphene layer.
  • the layered graphene structure is a hydrogel.
  • the spacer is a peptide.
  • the middle portion is hydrophilic.
  • the middle portion is a substantially rigid structure.
  • the middle portion has an alpha-helix structure.
  • the middle portion has a beta-sheet structure.
  • the upper end and lower end are connected to the middle portion flexible connecting units.
  • the flexible connecting units are glycine.
  • the upper end and lower end are amino acids.
  • the upper end and lower end are selected from the group of amino acids consisting of histidine, tyrosine, phenylalanine and tryptophan.
  • the upper end and lower end are the same.
  • the upper end and lower end are the not the same.
  • said structure is porous.
  • said structure is mesoporous, for example the pores are at least 2nm in diameter and less than 50nm in diameter.
  • said structure is macroporous, for example the pores are greater than 50nm in diameter.
  • said layered structure is at least 10nm thick. Preferably said layered structure is between 10-100nm thick.
  • said layered structure is greater than 100nm thick. In a further alternative embodiment of the invention said layered structure is between 100 to 1000nm thick.
  • said layered structure is greater than l OOOnm thick. In a further preferred embodiment of the invention said layered structure comprises at least 2 graphene layers. In a preferred embodiment of the invention said layered structure comprises at least 2 to 100 graphene layers.
  • said layered structure comprises greater than 100 graphene layers.
  • a device comprising a graphene structure according to the invention.
  • said device is a drug delivery device wherein said device is further modified to include at least one biologically active agent.
  • a "drug delivery device” is a generic term to include structures that facilitate the controlled release of a therapeutic agent.
  • drug delivery devices are adapted to deliver a drug of a particular dosage via a particular route of administration, for example intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, transdermal or trans-epithelial.
  • Drug delivery devices typically are engineered to release the associated therapeutic agent in a controlled release, for example immediate delayed or sustained release or combinations thereof.
  • a drug delivery device as a gel can be applied directly to, for example, a tumour or other diseased tissue to allow direct release of the drug at or on the diseased tissue.
  • a drug delivery device could also be a bandage or hydrogel adapted to contact a wound to administer a wound healing agent and/or an anti-microbial agent.
  • said device is a medical device.
  • Medical devices are implanted into patients to treat a variety of diseases and conditions. Medical devices include catheters, stents [ureteral or prostatic stents], cannulas, prosthesis and implants, gels.
  • the surfaces of medical devices can be adapted to release agents, for example therapeutic agents, that treat disease or reduce the likelihood of infection.
  • the implantation of a medical device necessarily requires the exposure of the patient to both immune rejection of the implanted device and also an increased probability of an adventitious infection by a microbial pathogen.
  • the invention therefore anticipates a device according to the invention that includes an agent to prevent immune rejection and/or an antimicrobial agent such as an antibiotic or heavy metal such as silver, gold or copper.
  • said therapeutic agent is an anticancer agent.
  • said drug delivery device comprises a gel.
  • a method of producing a layered graphene structure including the steps of: mixing graphene and a solution of spacer units having a first end group and a second end group in a solution; non-covalently bonding a first end group of the spacer unit to a first side of at least a first graphene sheet; non-covalently bonding a second end group of the spacer unit to a first side of at least a second graphene sheet; wherein the spacer units form a spacer layer, so as to provide a desired predetermined space between the at least first graphene sheet and the at least second graphene sheet.
  • the layered graphene structure is self-assembled.
  • the spacer units facilitates the self-assembly and stabilisation of the layered graphene structure.
  • the spacer unit is at least one amino acid. In preference, the spacer unit is at least one peptide.
  • the spacer unit is at least one polypeptide.
  • first end group and the second end group of the spacer units are selected from the group of functional groups including aromatic and non-aromatic functional groups.
  • iii) contacting the layered graphene comprising molecule[s] with a wash buffer to remove non-specifically associated molecules; optionally iv) repeating step ii) and/or iii);
  • step v) repeating step v).
  • said layered graphene is part of a column and said molecules are contacted with said layered graphene.
  • said layered graphene is contacted with a solution comprising a mixture of said molecules.
  • Microlecules refer to organic or inorganic compounds and encompasses proteins [e.g. enzymes, hormones, antibodies or antibody fragments, antigenic proteins and polypeptides found in vaccines, peptides such as peptide hormones, nucleic acids, [e.g. DNA fragments, cDNA, mRNA, plasmid and vector nucleic acid]. Also included are small organic molecules such as chemotherapeutic agents, antibiotics, anti-inflammatories.
  • proteins e.g. enzymes, hormones, antibodies or antibody fragments, antigenic proteins and polypeptides found in vaccines, peptides such as peptide hormones, nucleic acids, [e.g. DNA fragments, cDNA, mRNA, plasmid and vector nucleic acid].
  • nucleic acids e.g. DNA fragments, cDNA, mRNA, plasmid and vector nucleic acid.
  • small organic molecules such as chemotherapeutic agents, antibiotics, anti-inflammatories.
  • compositions and layered materials described herein may be tuned or customised based on the substitution or variation of the spacer units.
  • spacer units could be readily synthesised using conventional approaches to provide a particular property, for example the ability of the layered structure to act as a filter or detector of an analyte.
  • the resultant material may be used to trap or sequester a desired target molecule within a solution or mixture.
  • the spacer unit may be further functionalised to interact with the desired target molecule.
  • the compositions and layered materials of the present invention may be useful as electron transport materials in photovoltaic devices, such as solar cells. They may be combined with other materials such as electron conducting materials. Alternatively, compositions and layered materials of the present invention may be useful in applications such as conductive coatings, energy storage materials such as secondary batteries and supercapacitors, artificial photosynthetic devices for producing hydrogen from water and other nano-reactor applications.
  • the spacer units may be designed to respond or react to external stimuli so that the spacing between the graphene sheets are affected, for example, by changes in pH to the liquid in which the present invention is immersed. Changes in pH may change the length of the spacer units resulting in the space between the graphene sheets either increasing or decreasing.
  • the spacer units may also be designed to be able to reversibly or irreversibly disengage with the adjacent graphene sheets after formation of the composition of the present invention. In this way it may be possible to predetermine a point at which any components held within the present invention are released into its immediate environment or alternatively define a point at which the functioning of the present invention may be halted or adjusted.
  • the present invention provides a way in which the spacing between the graphene sheets can be controlled by way of modification of the size, shape and composition of the peptide.
  • chemotherapeutic agent is an agent that typically is a small chemical compound that preferably kills cells in particular diseased cells or tissue or is at least cytostatic. Agents can be divided with respect to their structure or mode of action.
  • chemotherapeutic agents include alkylating agents, anti-metabolites, anthracyclines, alkaloids, plant terpenoids and toposisomerase inhibitors.
  • Chemotherapeutic agents typically produce their effects on cell division or DNA synthesis. Examples of alkylating agents are cisplatin, carboplatin or oxaliplatin.
  • anti-metabolites include purine or pyrimidine analogues. Purine analogues are known in the art.
  • thioguanine is used to treat acute leukaemia. Fludarabine inhibits the function of DNA polymerases, DNA primases and DNA ligases and is specific for cell-cycle S-phase. Pentostatin and cladribine are adenosine analogues and are effective against hairy cell leukaemias. A further example is mercaptopurine which is an adenine analogue. Pyrimidine analogues are similarly known in the art. For example, 5-fluorouracil (5-FU), floxuridine and cytosine arabinoside. 5-FU has been used for many years in the treatment of breast, colorectal cancer, pancreatic and other cancers.
  • 5-FU can also been formed from the pro-drug capecitabine which is converted to 5-FU in the tumour.
  • Leucovorin also known as folic acid
  • Alkylating agents are also known in the art and include vinca alkaloids, for example vincristine or vinblastine. Terpenoids have been used for many years and include the taxanes, for example, palitaxel.
  • said agent is doxorubicin.
  • Prodrugs are also within the scope of the invention.
  • a prodrug is a substance that is converted from an inactive or partially active agent by chemical conversion, for example enzymatic conversion, to an active or more active drug.
  • the spacer according to the invention can be designed to accept small organic molecules as herein disclosed.
  • antibiotics and antiviral agents are effective in the treatment of microbial, for example bacterial and parasitic pathogens and pathogenic viruses.
  • classes of antibiotics effective in the control of bacterial pathogens include, by example only, penicillins, cephalosporins, rifamycins, sulphonamides, macrolides and tetracyclines.
  • antibacterial peptides such as dermicidins, cecropins and defensins.
  • Antiviral agents include anti-retroviral drugs such as zidovudine, lamivudine, efavirenz and abacavir; and anti-viral drugs such as ganciclovir, aciclovir and oseltamivir.
  • Anti-protozoan agents include lumefantrine, mefloquine, amodiaquine, sulfadoxine, chloroquine used in the treatment of malaria and also combination therapies that use these agents in combination with artemisinin. These are additional non-limiting examples of agents that can be used with the device according to the invention.
  • Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology. Typically antibodies are directed to cell surface proteins, for example receptors. However, intracellular delivery of antibodies and antibody fragments is known, for example see WO2007/064727; WO2004/030610; WO03/095641 ; WO02/07671 ; WO01/43778; WO96/40248; and WO94/01 131 each of which is incorporated by reference in their entirety.
  • Chimeric antibodies are recombinant antibodies in which all of the V-regions of a mouse or rat antibody are combined with human antibody C-regions.
  • Humanised antibodies are recombinant hybrid antibodies which fuse the complementarity determining regions from a rodent antibody V-region with the framework regions from the human antibody V- regions. The C-regions from the human antibody are also used.
  • the complementarity determining regions (CDRs) are the regions within the N-terminal domain of both the heavy and light chain of the antibody to where the majority of the variation of the V- region is restricted. These regions form loops at the surface of the antibody molecule. These loops provide the binding surface between the antibody and antigen.
  • Antibodies from non-human animals provoke an immune response to the foreign antibody and its removal from the circulation.
  • Both chimeric and humanised antibodies have reduced antigenicity when injected to a human subject because there is a reduced amount of rodent (i.e. foreign) antibody within the recombinant hybrid antibody, while the human antibody regions do not ellicit an immune response. This results in a weaker immune response and a decrease in the clearance of the antibody. This is clearly desirable when using therapeutic antibodies in the treatment of human diseases.
  • Humanised antibodies are designed to have less "foreign" antibody regions and are therefore thought to be less immunogenic than chimeric antibodies.
  • a Fab fragment is a multimeric protein consisting of the immunologically active portions of an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, covalently coupled together and capable of specifically binding to an antigen.
  • Fab fragments are generated via proteolytic cleavage (with, for example, papain) of an intact immunoglobulin molecule.
  • a Fab 2 fragment comprises two joined Fab fragments. When these two fragments are joined by the immunoglobulin hinge region, a F(ab') 2 fragment results.
  • An Fv fragment is multimeric protein consisting of the immunologically active portions of an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region covalently coupled together and capable of specifically binding to an antigen.
  • a fragment could also be a single chain polypeptide containing only one light chain variable region, or a fragment thereof that contains the three CDRs of the light chain variable region, without an associated heavy chain variable region, or a fragment thereof containing the three CDRs of the heavy chain variable region, without an associated light chain moiety; and multi specific antibodies formed from antibody fragments, this has for example been described in US patent No 6,248,516.
  • Fv fragments or single region (domain) fragments are typically generated by expression in host cell lines of the relevant identified regions.
  • immunoglobulin or antibody fragments are within the scope of the invention and are described in standard immunology textbooks such as Paul, Fundamental Immunology or Janeway et al. Immunobiology. Molecular biology now allows direct synthesis (via expression in cells or chemically) of these fragments, as well as synthesis of combinations thereof.
  • a fragment of an antibody or immunoglobulin can also have bispecific function as described above.
  • the device according to the invention can be adapted by manipulation of pore size to carry antibodies and antibody fragments as herein disclosed.
  • / ⁇ generally will be formulated and administered according to standard procedures. Exemplary doses can range from 10 to 250 ⁇ 9/ ⁇ , 30 ⁇ 9/ ⁇ to 250 g/ml, 50 ng/ml to 250 ng/ml, 30 such as 10 ⁇ g/ml, 20
  • compositions ⁇ g/ml or 500
  • Other protocols for the administration of compositions will be known to one of ordinary skill in the art, in which the dose amount, schedule of injections, sites of injections, mode of administration and the like vary from the foregoing.
  • the administration of compositions to mammals other than humans, is carried out under substantially the same conditions as described above.
  • a subject, as used herein, is a mammal, preferably a human, and including a non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent.
  • protein or peptide biologies can be associated with the device according to the invention.
  • Cytokines are involved in a number of diverse cellular functions. These include modulation of the immune system, regulation of energy metabolism and control of growth and development. Cytokines mediate their effects via receptors expressed at the cell surface on target cells. Examples of cytokines include the interleukins such as: IL1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32 and 33.
  • growth hormone examples include growth hormone, leptin, erythropoietin, prolactin, tumour necrosis factor [TNF] granulocyte colony stimulating factor (GCSF), granulocyte macrophage colony stimulating factor (GMCSF), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1 ), leukemia inhibitory factor (LIF) and oncostatin M (OSM), interferon a, interferon ⁇ , interferon ⁇ , interferon ⁇ and ⁇ interferon.
  • TNF tumour necrosis factor
  • GCSF granulocyte colony stimulating factor
  • GMCSF granulocyte macrophage colony stimulating factor
  • CNTF ciliary neurotrophic factor
  • CT-1 cardiotrophin-1
  • OSM oncostatin M
  • Examples of pharmaceutically active peptides include GLP-1 , anti-diuretic hormone; oxytocin; gonadotropin releasing hormone, corticotrophin releasing hormone; calcitonin, glucagon, amylin, A-type natriuretic hormone, B-type natriuretic hormone, ghrelin, neuropeptide Y, neuropeptide YY 3 _ 36, growth hormone releasing hormone, somatostatin; or homologues or analogues thereof.
  • chemokine refers to a group of structurally related low-molecular weight factors secreted by cells having mitogenic, chemotactic or inflammatory activities. They are primarily cationic proteins of 70 to 100 amino acid residues that share four conserved cysteine residues. These proteins can be sorted into two groups based on the spacing of the two amino-terminal cysteines. In the first group, the two cysteines are separated by a single residue (C-x-C), while in the second group they are adjacent (C-C).
  • Examples of member of the 'C-x-C chemokines include but are not limited to platelet factor 4 (PF4), platelet basic protein (PBP), interleukin-8 (IL-8), melanoma growth stimulatory activity protein (MGSA), macrophage inflammatory protein 2 (MIP-2), mouse Mig (m1 19), chicken 9E3 (or pCEF-4), pig alveolar macrophage chemotactic factors I and II (AMCF-I and -II), pre-B cell growth stimulating factor (PBSF).and IP10.
  • PF4 platelet factor 4
  • PBP platelet basic protein
  • IL-8 interleukin-8
  • MGSA melanoma growth stimulatory activity protein
  • MIP-2 macrophage inflammatory protein 2
  • mouse Mig m1 19
  • chicken 9E3 or pCEF-4
  • pig alveolar macrophage chemotactic factors I and II AMCF-I and -II
  • PBSF pre-B cell growth stimulating factor
  • Examples of members of the 'C-C group include but are not limited to monocyte chemotactic protein 1 (MCP-1 ), monocyte chemotactic protein 2 (MCP-2), monocyte chemotactic protein 3 (MCP-3), monocyte chemotactic protein 4 (MCP-4), macrophage inflammatory protein 1 a (MIP-1- a), macrophage inflammatory protein 1 ⁇ (MIP-1 - ⁇ ), macrophage inflammatory protein 1- ⁇ (MIP-1 - ⁇ ), macrophage inflammatory protein 3 a (MIP-3-a, macrophage inflammatory protein 3 ⁇ (MIP-3- ⁇ ), chemokine (ELC), macrophage inflammatory protein-4 (MIP-4), macrophage inflammatory protein 5 (MIP-5), LD78 ⁇ , RANTES, SIS-epsilon (p500), thymus and activation-regulated chemokine (TARC), eotaxin, I-309, human protein HCC- 1/NCC-2, human protein HCC-3.
  • VEGF A vascular endothelial growth factor
  • VEGF B vascular endothelial growth factor
  • VEGF C vascular endothelial growth factor
  • VEGF D transforming growth factor
  • TGFb transforming growth factor
  • aFGF and bFGF acidic and basic fibroblast growth factor
  • PDGF platelet derived growth factor
  • VEGF is an endothelial cell-specific growth factor which has a very specific site of action, namely the promotion of endothelial cell proliferation, migration and differentiation.
  • VEGF is a complex comprising two identical 23 kD polypeptides.
  • VEGF can exist as four distinct polypeptides of different molecular weight, each being derived from an alternatively spliced mRNA.
  • bFGF is a growth factor that functions to stimulate the proliferation of fibroblasts and endothelial cells.
  • bFGF is a single polypeptide chain with a molecular weight of 16.5Kd.
  • Several molecular forms of bFGF have been discovered which differ in the length at their amino terminal region. However the biological function of the various molecular forms appears to be the same.
  • Pro-drug activating polypeptides are also within the scope of the invention.
  • the term pro- drug activating genes refers to nucleotide sequences, the expression of which, results in the production of proteins capable of converting a non-therapeutic compound into a therapeutic compound, which renders the cell susceptible to killing by external factors or causes a toxic condition in the cell.
  • An example of a prodrug activating gene is the cytosine deaminase gene. Cytosine deaminase converts 5-fluorocytosine to 5 fluorouracil, a potent anti-tumour agent.
  • the lysis of the tumour cell provides a localized burst of cytosine deaminase capable of converting 5FC to 5FU at the localized point of the tumour resulting in the killing of many surrounding tumour cells.
  • TK thymidine kinase
  • Other examples of pro-drug activating enzymes are nitroreductase and cytochrome p450's (e.g. CYP1A2, CYP2E1 or CYP3A4).
  • Figure 1 summarizes the principles of the invention (the solution molecules and ions required to maintain an appropriate solution condition (e.g. neutral) have been omitted for clarity);
  • Figure 2 shows a view of an example of the present invention, a reduced graphene oxide (rGO) layered hydrogel construct of approximately 5 ⁇ thickness obtained via peptide- directed self-assembly using the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3] and the method described herein (see Methods for details);
  • rGO reduced graphene oxide
  • Figure 3 shows a view of another example of the present invention, a reduced graphene oxide layered hydrogel construct of approximately 70 nm thickness obtained via peptide- directed self-assembly using the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3] and supported on a glass slide (see Methods for details) that is sat on top of some written text on a piece of paper;
  • Figure 4 shows an SEM image of a freeze dried sample of the hydrogel shown in Figure 2 edge on (see Methods for details);
  • Figure 5 top shows on an AFM image two independent paths A-B and C-D taken by the AFM probe for a sample of the material shown in Figure 2 (see Methods for details), and the AFM probe height along the two paths (middle and bottom) showing the distance between successive rGO sheets separated by the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3] (i.e. the pore size) that has been designed to yield a pore size of 2.6 nm;
  • Figure 6 shows the variation with time of doxorubicin (DOX) anti-cancer drug uptake (see Methods for details) for different rGO hydrogels formed using the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3] where the degree of reduction of the rGO is different (the take-up for the rGO hydrogel formed in the absence of the peptide is also shown for reference);
  • Figure 7 shows the DOX release profile at different pH values (see Methods for details) for the optimal rGO hydrogel formed using the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3];
  • Figure 8 shows the results of an MTT assay based analysis (see Methods for details) to assess the toxicity of different concentrations of the rGO hydrogel formed using the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3];
  • Figure 9 shows the results of an MTT assay based analysis (see Methods for details) to assess the toxicity of DOX alone and DOX released from the hydrogel formed using the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3];
  • Figure 10 shows the variation with time of uptake of three different sized dextran molecules (see Methods for details) for an rGO hydrogel formed using the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3].
  • Graphene oxide was prepared from natural or synthetic graphite according to the improved Hummer's method. 37 Briefly, a 9:1 mixture of concentrated sulphuric acid and phosphoric acid (120:13 mL) was cooled overnight to 4 °C. The already cooled acid mixture was slowly added to the graphite powder (1 g) and potassium permanganate (6 g) under stirring at room temperature. Then the mixture was heated to 50 °C for 12 h to form a thick paste. The paste was then cooled to room temperature and then poured onto ice cubes (150 mL of Milli-Q water) with 30% hydrogen peroxide (1 mL).
  • the mixture was then washed and filtered with distilled water and hydrochloric acid (32 %) followed by repeated washing with ethanol and eventually with Milli-Q water.
  • the obtained brown dispersion was centrifuged at 4400 rpm for 2 h to remove residual salts and any un-exfoliated graphite oxide, which is usually present in a very small amount.
  • the obtained GO was vacuum dried overnight at room temperature.
  • rGO reduced GO
  • 25 imL of a homogeneous dispersion of GO 0.5 mg/ml
  • a volumetric flask 25 ⁇ of hydrazine solution (35 wt% in water) and 75.0 ⁇ of ammonia solution (28 wt% in water)
  • the dispersion was vigorously stirred for a few minutes before being placed in a silicon oil bath ( ⁇ 95 °C) for 1 hr.
  • Other instances of rGO with different levels of GO reduction from ⁇ 20 wt% oxygen down to ⁇ 8% wt% oxygen were obtained by varying the hydrazine volume between 25 and 75 ⁇ and the reaction temperature between 85 and 95 °C.
  • One instance of the layered rGO hydrogel material with a dominant inter-sheet spacing (i.e. pore size) of 2.6 nm was produced by adding 25 mL of rGO dispersion (0.5 mg/mL) to 25 mL of a solution of the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3] (0.10 ⁇ ) and then stirring for 30 min before filtering it through a mixed cellulose ester filter membrane (47mm in diameter, 0.05 ⁇ pore size, Millipore) by vacuum filtration. The resultant hydrogel film was then washed three times and immediately transferred to a Petri dish and immersed in Milli-Q water overnight to remove the remaining unbound peptide.
  • a mixed cellulose ester filter membrane 47mm in diameter, 0.05 ⁇ pore size, Millipore
  • rGO hydrogel material with a dominant pore size of 2.6 nm were obtained by using rGO dispersions with concentrations varying from 0.0025 mg/mL upwards in the aforementioned process.
  • the thickness of the resultant hydrogel films varied from 10s of nm, which meant they needed to be supported; an as-received glass microscope slide was used for this purpose, but it is anticipated that other materials could also be used.
  • the hydrogel films were transferred from the filter membrane to the glass slide support by tightly clamping the filter membrane supported hydrogel film between two glass slides for 12 h at room temperature before dissolving away the filter membrane with acetone.
  • the morphologies of the graphene hydrogel films prepared as described above were investigated using a scanning electron microscope (SEM; QUANTA 450).
  • SEM scanning electron microscope
  • the hydrogels were cut using a razor blade then dried in a freeze dryer (188K at 10 2 Pa for 24hrs),and then mounted in a cross-sectional sample holder before being imaged in the SEM.
  • the spacing between the individual rGO or GO sheets was assessed by atomic force microscopy (AFM; NT-MDT Ntegra Solaris) in tapping mode.
  • AFM atomic force microscopy
  • the AFM samples were prepared by drop-casting a diluted suspension of crushed hydrogel film onto a cleaned mica substrate. They were imaged immediately after preparation.
  • FITC-dextran-4k (FD4, Sigma- Aldrich; mol. wt. 4000, Stokes radius -1.4 nm); FITC-dextran-10k (FD10, Sigma- Aldrich; mol. wt. 10,000, Stokes radius -2.3 nm); and FITC-dextran-20k (FD20, Sigma-Aldrich; mol. wt. 20,000, Stokes radius -3.3 nm).
  • CHEMUSB4 Ocean Optics
  • the loading of doxorubicin (DOX) anti-cancer drug into the rGO hydrogels was assessed using a technique similar to that used to assess the filtration capability of the hydrogel. After adding 15 mg of the hydrogel to 3 mL of the DOX solution (50 g/mL) in a cuvette, the concentration of the latter was monitored in real time for 24 h by a UV-VIS spectrometer (USB4000-UV-VIS, Ocean Optics) operating at 490 nm. The variation of the drug loading in the hydrogel with time was estimated from this.
  • DOX doxorubicin
  • the DOX-loaded film was first removed from the drug loading cuvette and rinsed several times with deionized water to remove unbound drug and drug attached to the outer surface of the hydrogels. The film was then divided into three roughly equal parts before then being immersed in three separate cuvettes containing a 3 ml. aqueous PBS solution at 37 °C and pH 5.4, 7.4 and 9.4 respectively to mimic the release profile in physiological acidic, neutral and basic environments. The solutions in the cuvettes were constantly stirred whilst being maintained at 37 °C. At predetermined time intervals, 1 ml. of the solution from the cuvettes was withdrawn (with 1 mL of fresh PBS solution replacing it) to determine the DOX release using UV-Vis spectroscopy. Cell viability assessments
  • the toxicities of the graphene hydrogel, DOX and DOX-loaded hydrogel were assessed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium assay in a microplate reader.
  • MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
  • MSC Mesenchymal stem cells
  • Cell treatment with target to be assessed Cells were then cultured in medium with the target to be assessed (hydrogel, DOX, DOX-loaded hydrogel) for 24 hours. A control containing only the cells and no hydrogel was also included. Three replicate wells were used per sample, including the control.
  • MTT assay 10 ⁇ _ of MTT (5 mg/ml in PBS) were added to each well, including both samples and controls, and then incubated for 4 h at 37 °C. All the liquid was then removed from wells, transferred into new microplate and 150 ⁇ _ dimethyl sulfoxide (DMSO) was added to each well to ensure complete solubilization of formazan crystals.
  • DMSO dimethyl sulfoxide
  • the invention here centres on a peptide that is designed to self-assemble graphene sheets with a specific distance between the sheets, h, and which is composed of the following:
  • the middle part (at least one of) that prefers to sit in the solution phase between the two graphene sheets (e.g. it is overall hydrophilic when the solution is aqueous);
  • Figure 2 shows an example of an instance of an rGO hydrogel dominated by pores of 2.6 nm width produced using 25 mL of a 0.5 mg/mL rGO dispersion and 25 ml. of a 0.10 ⁇ solution of the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3], which was designed to yield a pore size of 2.6 nm.
  • the hydrogel film shown here is an approximately 5 ⁇ thick paper-like material that is flexible and non-brittle.
  • Figure 3 shows an example of an instance of an rGO hydrogel dominated by pores of 2.6 nm width produced using 100 mL of 0.0025 mg/mL rGO dispersion and 100 mL of a 0.0005 ⁇ solution of the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3], which was designed to yield a pore size of 2.6 nm.
  • the hydrogel film is approximately 70 nm thick and, thus, requires support on a surface (a microscope glass slide in this example).
  • Example 6 Figure 6 shows that the amount of doxorubicin (DOX) anti-cancer drug that can be loaded into a hydrogel made using the peptide FFGGEEEEEEGGFF [SEQ ID NO: 3] is a strong function of the level of reduction of the rGO: whilst the highly reduced rGO-based hydrogel is marginally better than the mildly-reduced rGO, significantly higher loadings can be achieved by identifying the optimal degree of reduction. This figure also shows that the pores created by use of the peptide increases substantially the DOX capacity of the hydrogel.
  • DOX doxorubicin
  • Example 7 Figure 7 shows that after an initial low level burst effect (less than 10%), the DOX only continues to be released to any significant extent under acidic conditions akin to those typical of tumour sites.
  • the release rate is sustained at an essentially constant value for around 3.5 days before release halts. Release beyond this point could possibly be enhanced by further optimisation of the hydrogel.
  • hydrogel by itself appears to be non-toxic as shown in Figure 8, which shows that cell viability over a 24 hour period was statistically invariant from the control (no hydrogel) for the case where 5, 10, 15, 20 and 25 mg of hydrogel were present.
  • Figure 9 compares the cell toxicity of 5 ⁇ g of DOX in 24 hours provided via 100 ⁇ _ of a 50 ⁇ g/mL DOX solution (DOX-only) and 15 mg of a hydrogel loaded with approximately 150 g of DOX that releases 5 ⁇ g in the 24 hours assessed (DOX-loaded hydrogel). This shows that the hydrogel-loaded DOX possesses a toxicity that is similar to that of DOX- only. As the hydrogel contains around 30 times this dose with approximately 60% of that being released based on the current realisation (see Figure 7), the hydrogel can deliver the required does in a sustained way for around 3.5 days without intervention. Longer periods could be achieved by increasing the mass of hydrogel or improving its formulation to ensure more than 60% of the DOX were released from the sample.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des molécules d'espacement et leur utilisation dans la formation de graphène en couches ainsi que des matériaux, des structures et des procédés associés pour produire du graphène en couches par auto-assemblage et des structures associées à taille de pores contrôlée.
PCT/AU2015/000034 2014-01-30 2015-01-28 Structures à base de carbone auto-assemblées et procédés associés Ceased WO2015113102A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014900273A AU2014900273A0 (en) 2014-01-30 Compositions comprising self assembled carbon based structures and related methods
AU2014900273 2014-01-30

Publications (1)

Publication Number Publication Date
WO2015113102A1 true WO2015113102A1 (fr) 2015-08-06

Family

ID=53756033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2015/000034 Ceased WO2015113102A1 (fr) 2014-01-30 2015-01-28 Structures à base de carbone auto-assemblées et procédés associés

Country Status (1)

Country Link
WO (1) WO2015113102A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115193275A (zh) * 2022-07-08 2022-10-18 中国科学院生态环境研究中心 电响应膜及其制备方法和应用
CN115739151A (zh) * 2022-11-04 2023-03-07 山西大学 一种氮掺杂石墨烯担载磁性纳米颗粒材料的制备与应用
CN116555346A (zh) * 2023-07-05 2023-08-08 中山大学 一种采用碳纳米管基因载体递送系统促进草鱼生长的方法
WO2023220688A1 (fr) * 2022-05-11 2023-11-16 The Johns Hopkins University Ingénierie de peptides multifonctionnels pour administration contrôlée de médicaments

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092360A2 (fr) * 2003-04-10 2004-10-28 Chiron Corporation Le coronavirus du syndrome respiratoire aigu grave
WO2009039854A2 (fr) * 2007-09-27 2009-04-02 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
WO2011119484A1 (fr) * 2010-03-23 2011-09-29 Iogenetics, Llc Procédés bioinformatiques pour déterminer la liaison de peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092360A2 (fr) * 2003-04-10 2004-10-28 Chiron Corporation Le coronavirus du syndrome respiratoire aigu grave
WO2009039854A2 (fr) * 2007-09-27 2009-04-02 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
WO2011119484A1 (fr) * 2010-03-23 2011-09-29 Iogenetics, Llc Procédés bioinformatiques pour déterminer la liaison de peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADHIKARI, B. ET AL.: "Short peptide based hydrogels: incorporation of graphene into the hydrogel.", SOFT MATTER, vol. 7, 2011, pages 9259 - 9266, XP055216420 *
XU, Y ET AL.: "Flexible Graphene Films via the Filtration of Water-Soluble Nonconvalent Functionalized Graphene Sheets.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 130, 2008, pages 5856 - 5857, XP055216425 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220688A1 (fr) * 2022-05-11 2023-11-16 The Johns Hopkins University Ingénierie de peptides multifonctionnels pour administration contrôlée de médicaments
CN115193275A (zh) * 2022-07-08 2022-10-18 中国科学院生态环境研究中心 电响应膜及其制备方法和应用
CN115193275B (zh) * 2022-07-08 2023-07-18 中国科学院生态环境研究中心 电响应膜及其制备方法和应用
CN115739151A (zh) * 2022-11-04 2023-03-07 山西大学 一种氮掺杂石墨烯担载磁性纳米颗粒材料的制备与应用
CN116555346A (zh) * 2023-07-05 2023-08-08 中山大学 一种采用碳纳米管基因载体递送系统促进草鱼生长的方法
CN116555346B (zh) * 2023-07-05 2023-09-01 中山大学 一种采用碳纳米管基因载体递送系统促进草鱼生长的方法

Similar Documents

Publication Publication Date Title
Rabiee et al. Natural polymers decorated MOF-MXene nanocarriers for co-delivery of doxorubicin/pCRISPR
Cha et al. Carbon-based nanomaterials: multifunctional materials for biomedical engineering
Priyadarsini et al. Graphene and graphene oxide as nanomaterials for medicine and biology application
Luo et al. Carbon nanotube nanoreservior for controlled release of anti-inflammatory dexamethasone
Iravani et al. MXenes and MXene-based materials for tissue engineering and regenerative medicine: Recent advances
Amani et al. Three-dimensional graphene foams: synthesis, properties, biocompatibility, biodegradability, and applications in tissue engineering
Ma et al. Multifunctional MXene-based bioactive materials for integrated regeneration therapy
Zhou et al. Application of graphene/graphene oxide in biomedicine and biotechnology
Girao et al. 3D reduced graphene oxide scaffolds with a combinatorial fibrous-porous architecture for neural tissue engineering
Grant et al. Biomedical applications of electrospun graphene oxide
Cheng et al. Functional graphene nanomaterials based architectures: biointeractions, fabrications, and emerging biological applications
Jin et al. Biocompatible, free-standing film composed of bacterial cellulose nanofibers–graphene composite
Ansari et al. Graphene and graphene-based materials in biomedical applications
Liu et al. Organoid extracellular vesicle-based therapeutic strategies for bone therapy
Lalwani et al. Two-and three-dimensional all-carbon nanomaterial assemblies for tissue engineering and regenerative medicine
CN104189910A (zh) 一种用于药物缓释的氧化石墨烯薄膜制备方法以及产品
Ou et al. Graphene-based material-mediated immunomodulation in tissue engineering and regeneration: mechanism and significance
WO2015113102A1 (fr) Structures à base de carbone auto-assemblées et procédés associés
Petrov et al. Peptide and protein‐based nanotubes for nanobiotechnology
Li et al. Delivery of interleukin 4 from a titanium substrate coated with graphene oxide for enhanced osseointegration by regulating macrophage polarization
Farr et al. Nanomaterial additives for fabrication of stimuli‐responsive skeletal muscle tissue engineering constructs
Qian et al. Construction of Fe3O4-loaded mesoporous carbon systems for controlled drug delivery
Raja et al. Virus-incorporated biomimetic nanocomposites for tissue regeneration
Zhang et al. Effects of Graphene‐Based Materials on the Behavior of Neural Stem Cells
Pieklarz et al. Current progress in biomedical applications of chitosan-carbon nanotube nanocomposites: a review

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15743512

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15743512

Country of ref document: EP

Kind code of ref document: A1